Myriad Genetics Inc

NASDAQ:MYGNUnited States

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company primarily provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing the disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression, and includes corporate services, such as finance, human resources, legal and information technology. The Company discovers and commercializes genetic tests. The Company's products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight and Prequel, GeneSight, Vectra. The Company offers SneakPeek Early Gender DNA Test, which reveals a baby’s gender at six weeks into pregnancy. Its wholly owned subsidiaries include Myriad Genetic Laboratories, Inc., Assurex Health, Inc. and Myriad Women’s Health, Inc.

Contact Information

Headquarters

320 Wakara WaySALT LAKE CITY, UT, United States 84108

Phone

801-584-3600

Fax

801-584-3640

Executives

Independent Chairman of the Board

S. Louise Phanstiel

President, Chief Executive Officer, Director

Paul Diaz

Chief Financial Officer, Treasurer

R. Bryan Riggsbee

Chief Operating Officer

Nicole Lambert

Chief People Officer

Jayne Hart